On the other hand, in patients with nonalcoholic fatty liver disease (NAFLD), ALT and AST were significantly reduced [57], mostly in studies that lasted over 3 months and in patients with mean age < 45 years and BMI < 30kg/m2. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.